Primo Biotechnology Secures Funding for Expansion
Primo Biotechnology Co., Ltd., a trailblazing company in the field of radiopharmaceuticals, proudly announced the successful closure of a significant funding round, raising NT$220 million. This effort has significantly increased their total capital, now surpassing NT$500 million. Such financial backing underscores the company's commitment to becoming a leader in radioligand theranostics, which involves innovative treatments for cancer focusing on precision medicine. Furthermore, the company is on track to pursue an IPO in 2026, tapping into public markets to boost its research and development capabilities and broaden its global footprint.
Leadership Insights on Research and Development
Dr. Ya-Yao Huang, the inspiring CEO and co-founder of Primo Biotechnology, emphasized the company's dedication to advancing the next wave of Radioligand Theranostics (RLT). Through state-of-the-art precision treatments, the company aims to revolutionize cancer care. Notably, their radiopharmaceutical facility achieved prestigious certifications in PIC/S GMP and GDP, reflecting rigorous standards in drug manufacturing quality. Dr. Huang remarked that the recent fundraising will significantly bolster their drug development initiatives and expedite the advancement of radiodiagnostics and therapeutic solutions in the region.
Strategic Partnerships and Innovations
In exciting developments, Primo has officially partnered with ABX advanced biochemical compounds GmbH, a recognized leader in the radiopharmaceutical landscape, allowing them to manufacture and distribute the prostate cancer diagnostic product "Radelumin ([18F]PSMA-1007)" in Taiwan. This innovative product, already approved in multiple countries, was supplied for clinical use in Taiwan recently, marking a pivotal step in the local cancer diagnostics arena.
Expanding Pipeline and Clinical Trials
Beyond the prostate cancer diagnostic advancements, Primo is poised to widen its clinical trial scopes for their pipeline candidates, PB011 and PB012, targeting additional cancer indications. The company is strategically leveraging Taiwan's streamlined Category 2 drug registration pathway, which drastically reduces the costs, time, and risks typically associated with new drug approvals. This targeted approach not only facilitates quicker market entry but also sets the stage for accelerated revenue generation that can further finance radiopharmaceutical innovations.
About Primo Biotechnology Co., Ltd.
Primo Biotechnology Co., Ltd. stands at the forefront of the biopharmaceutical sector, specializing in the development and production of radiopharmaceutical products that lead the charge in precision cancer care. With cutting-edge facilities recognized internationally and a commitment to advanced molecular imaging and targeted therapies, Primo strives to offer innovative solutions that enhance the lives of cancer patients globally. Based in Taipei, the company actively collaborates with both national and international partners to catalyze progress in precision oncology, utilizing its capabilities in drug development and GMP manufacturing.
Frequently Asked Questions
What is Primo Biotechnology's recent funding achievement?
Primo has successfully raised NT$220 million, bringing its total capital to over NT$500 million, enhancing its research capabilities.
What are the company's future plans for IPO?
Primo Biotechnology is planning to launch an IPO in 2026 to leverage public market resources for its expansion.
What partnerships has Primo formed recently?
Primo has partnered with ABX advanced biochemical compounds GmbH to distribute radiopharmaceuticals in Taiwan.
Which products is Primo focusing on?
They are developing the prostate cancer diagnostic product Radelumin and expanding their pipeline with candidates PB011 and PB012.
How does Primo aim to expedite its drug development process?
Primo utilizes Taiwan's Category 2 new drug registration pathway, which helps bring products to market faster and more affordably.
